A 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies.

There has been great interest in genetic risk prediction using risk scores in recent years, however, the utility of scores developed in European populations and later applied to non-European populations has not been successful. The goal of this study was to create a methylation risk score (MRS) for...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bertha A Hidalgo, Bre Minniefield, Amit Patki, Rikki Tanner, Minoo Bagheri, Hemant K Tiwari, Donna K Arnett, Marguerite Ryan Irvin
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/497a6248df3448a8a7ae3bc451ee5293
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:497a6248df3448a8a7ae3bc451ee5293
record_format	dspace
spelling	oai:doaj.org-article:497a6248df3448a8a7ae3bc451ee52932021-12-02T20:13:07ZA 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies.1932-620310.1371/journal.pone.0259836https://doaj.org/article/497a6248df3448a8a7ae3bc451ee52932021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0259836https://doaj.org/toc/1932-6203There has been great interest in genetic risk prediction using risk scores in recent years, however, the utility of scores developed in European populations and later applied to non-European populations has not been successful. The goal of this study was to create a methylation risk score (MRS) for metabolic syndrome (MetS), demonstrating the utility of MRS across race groups using cross-sectional data from the Hypertension Genetic Epidemiology Network (HyperGEN, N = 614 African Americans (AA)) and the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN, N = 995 European Americans (EA)). To demonstrate this, we first selected cytosine-guanine dinucleotides (CpG) sites measured on Illumina Methyl450 arrays previously reported to be significantly associated with MetS and/or component conditions in more than one race/ethnic group (CPT1A cg00574958, PHOSPHO1 cg02650017, ABCG1 cg06500161, SREBF1 cg11024682, SOCS3 cg18181703, TXNIP cg19693031). Second, we calculated the parameter estimates for the 6 CpGs in the HyperGEN data (AA) and used the beta estimates as weights to construct a MRS in HyperGEN (AA), which was validated in GOLDN (EA). We performed association analyses using logistic mixed models to test the association between the MRS and MetS, adjusting for covariates. Results showed the MRS was significantly associated with MetS in both populations. In summary, a MRS for MetS was a strong predictor for the condition across two race groups, suggesting MRS may be useful to examine metabolic disease risk or related complications across race/ethnic groups.Bertha A HidalgoBre MinniefieldAmit PatkiRikki TannerMinoo BagheriHemant K TiwariDonna K ArnettMarguerite Ryan IrvinPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11, p e0259836 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Bertha A Hidalgo Bre Minniefield Amit Patki Rikki Tanner Minoo Bagheri Hemant K Tiwari Donna K Arnett Marguerite Ryan Irvin A 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies.
description	There has been great interest in genetic risk prediction using risk scores in recent years, however, the utility of scores developed in European populations and later applied to non-European populations has not been successful. The goal of this study was to create a methylation risk score (MRS) for metabolic syndrome (MetS), demonstrating the utility of MRS across race groups using cross-sectional data from the Hypertension Genetic Epidemiology Network (HyperGEN, N = 614 African Americans (AA)) and the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN, N = 995 European Americans (EA)). To demonstrate this, we first selected cytosine-guanine dinucleotides (CpG) sites measured on Illumina Methyl450 arrays previously reported to be significantly associated with MetS and/or component conditions in more than one race/ethnic group (CPT1A cg00574958, PHOSPHO1 cg02650017, ABCG1 cg06500161, SREBF1 cg11024682, SOCS3 cg18181703, TXNIP cg19693031). Second, we calculated the parameter estimates for the 6 CpGs in the HyperGEN data (AA) and used the beta estimates as weights to construct a MRS in HyperGEN (AA), which was validated in GOLDN (EA). We performed association analyses using logistic mixed models to test the association between the MRS and MetS, adjusting for covariates. Results showed the MRS was significantly associated with MetS in both populations. In summary, a MRS for MetS was a strong predictor for the condition across two race groups, suggesting MRS may be useful to examine metabolic disease risk or related complications across race/ethnic groups.
format	article
author	Bertha A Hidalgo Bre Minniefield Amit Patki Rikki Tanner Minoo Bagheri Hemant K Tiwari Donna K Arnett Marguerite Ryan Irvin
author_facet	Bertha A Hidalgo Bre Minniefield Amit Patki Rikki Tanner Minoo Bagheri Hemant K Tiwari Donna K Arnett Marguerite Ryan Irvin
author_sort	Bertha A Hidalgo
title	A 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies.
title_short	A 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies.
title_full	A 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies.
title_fullStr	A 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies.
title_full_unstemmed	A 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies.
title_sort	6-cpg validated methylation risk score model for metabolic syndrome: the hypergen and goldn studies.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/497a6248df3448a8a7ae3bc451ee5293
work_keys_str_mv	AT berthaahidalgo a6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT breminniefield a6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT amitpatki a6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT rikkitanner a6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT minoobagheri a6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT hemantktiwari a6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT donnakarnett a6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT margueriteryanirvin a6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT berthaahidalgo 6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT breminniefield 6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT amitpatki 6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT rikkitanner 6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT minoobagheri 6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT hemantktiwari 6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT donnakarnett 6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies AT margueriteryanirvin 6cpgvalidatedmethylationriskscoremodelformetabolicsyndromethehypergenandgoldnstudies
_version_	1718374820858560512

A 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies.

Ejemplares similares